Technology’s Role In Advancing Outcomes & Reducing The Cost Of Care For The SMI Population is starting in

Warning Letter: Liveyon Labs, Inc.

On December 5, 2019, the Office of Biological Products Operations sent a warning letter to Liveyon Labs Inc. The letter outlines that during an inspection of Liveyon Labs Inc. and Liveyon LLC conducted in May 2019, the Food and Drug Administration documented that the organization processes human umbilical cord blood derived cellular products PURE® and PURE PRO® for allogeneic use . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Tagged As: